



MOCHIDA PHARMACEUTICAL CO., LTD.

January 17, 2025

General Announcement:

Senju Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd.

Senju has Applied for Manufacturing and Marketing Approval in Japan
for the novel Dry Eye Disease treatment, SJP-0132

Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) is developing a TRPV1 antagonist (development code: SJP-0132) discovered by Mochida Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President: Mr. Naoyuki Mochida; hereinafter: Mochida) and licensed to Senju as an eye drop treatment for Dry Eye Disease (DED). We are pleased to announce today that it has been applied for manufacturing and marketing approval in Japan.

DED, the target disease of SJP-0132, is defined as “A multifactorial disease characterized by an unstable tear film causing discomfort and/or visual impairment, accompanied by ocular surface disorder” *. Recently, the number of DED patients has been increasing due to an aging population, the long-term use of contact lenses, and the widespread use of Visual Display Terminals (VDT) such as PCs and Smartphones.

Senju is committed to obtaining marketing approval for the DED treatment SJP-0132 to provide patients with new options for alleviating the signs and symptoms of this disease.

Mochida is dedicated to leveraging its foresight and innovation to further its involvement in drug discovery research, and thereby continue its contributions toward improving the quality of life for patients.

* “Dry Eye Diagnostic Guidelines” Japan Dry Eye Society (2019)

[Contact details for inquiries]

Communications Department, Senju Pharmaceutical Co., Ltd.

3-1-9, Kawara-machi, Chuo-ku, Osaka 541-0048, Japan

Mail : cc@senju.co.jp

Public Relations, Mochida Pharmaceutical Co., Ltd.

7, Yotsuya 1-chome, Shinjuku-ku, Tokyo 160-8515, Japan

Mail : webmaster@mochida.co.jp